WallStreetZenWallStreetZen

NASDAQ: RNAC
Cartesian Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

RNAC past revenue growth

How has RNAC's revenue growth performed historically?
Company
-76.53%
Industry
154.55%
Market
17.87%
RNAC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RNAC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RNAC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RNAC earnings and revenue history

Current Revenue
$26.0M
Current Earnings
-$219.7M
Current Profit Margin
-844.9%

RNAC Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when RNAC announces earnings.

RNAC Return on Assets

Current Company
-124.4%
Current Industry
2.9%
RNAC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RNAC Return on Capital Employed

Current Company
-99.59%
Current Industry
19.5%
RNAC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RNAC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RNAC$26.00M-$233.28M-$219.71M+95.83%N/A
BRNS$802.00k-$69.64M-$73.35M-41.49%N/A
GNLX$170.00k-$27.63M-$28.30M-98.46%N/A
PDSB$0.00-$42.87M-$42.94MN/AN/A
ANIX$210.00k-$10.70M-$10.74M-28.36%N/A
View Top Biotech Stocks

RNAC earnings dates

Next earnings date
May 2, 2024

Cartesian Therapeutics Earnings & Revenue FAQ

What were RNAC's earnings last quarter?

On Invalid Date, Cartesian Therapeutics (NASDAQ: RNAC) reported Q4 2023 earnings per share (EPS) of -$41.70, up 4,733.33% year over year. Total Cartesian Therapeutics earnings for the quarter were -$177.66 million. In the same quarter last year, Cartesian Therapeutics's earnings per share (EPS) was $0.90.

If you're new to stock investing, here's how to buy Cartesian Therapeutics stock.

What was RNAC's earnings growth in the past year?

As of Q2 2024, Cartesian Therapeutics's earnings has grown year over year. Cartesian Therapeutics's earnings in the past year totalled -$219.71 million.

What is RNAC's earnings date?

Cartesian Therapeutics's earnings date is Invalid Date. Add RNAC to your watchlist to be reminded of RNAC's next earnings announcement.

What was RNAC's revenue last quarter?

On Invalid Date, Cartesian Therapeutics (NASDAQ: RNAC) reported Q4 2023 revenue of $8.27 million up 50.78% year over year. In the same quarter last year, Cartesian Therapeutics's revenue was $16.80 million.

What was RNAC's revenue growth in the past year?

As of Q2 2024, Cartesian Therapeutics's revenue has grown -76.53% year over year. This is 231.08 percentage points lower than the US Biotechnology industry revenue growth rate of 154.55%. Cartesian Therapeutics's revenue in the past year totalled $26.00 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.